Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Repligen (RGEN)
:RGEN
Holding RGEN?
Track your performance easily
RGEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$113.50 - $211.13
Previous CloseN/A
Volume111.19K
Average Volume (3M)504.22K
Market Cap
$8.99B
Enterprise Value$8.22B
Total Cash (Recent Filing)$141.78M
Total Debt (Recent Filing)$95.27M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Feb 19, 2025EPS Estimate
0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding56,026,726
10 Day Avg. Volume579,558
30 Day Avg. Volume504,217
Standard Deviation0.12
R-Squared0.17
Alpha0.00368
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)14.60
Price to Cash Flow (P/CF)45.60
P/FCF Ratio53.30
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue13.35
Enterprise Value/Gross Profit28.87
Enterprise Value/Ebitda103.53
Forecast
1Y Price Target
$198.17Price Target Upside23.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Repligen News
PremiumCompany Announcements
Repligen’s Strong Q3 and Strategic Moves
PremiumCompany Announcements
Repligen Reports Strong Q3 2024 with Revenue GrowthBulls Say, Bears Say
Bulls Say
Financial PerformanceRepligen delivered revenue of $155M, beating consensus expectations and marking a record revenue quarter.
Product InnovationA steady cadence of around 10 new product launches per year has significantly contributed to revenue growth, showcasing Repligen's innovation strength.
Profit MarginsGross margin exceeded consensus expectations, highlighting solid operational efficiency and profitability.
Bears Say
Headwinds And UncertaintiesThere are lingering questions on headwinds from China and equipment, which are key to stock upside.
Regional PerformanceGrowth was positive across all regions except for China, which showed soft performance despite encouraging quarter-over-quarter order signals.
Revenue ConcernsThe implied growth rates are negatively impacted due to the $6.6M of Covid fee revenue that won't recur.
---
Ownership Overview
0.70% Insiders
38.26% Mutual Funds
0.04% Other Institutional Investors
39.91% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RGEN FAQ
What was Repligen’s price range in the past 12 months?
Repligen lowest stock price was $113.50 and its highest was $211.13 in the past 12 months.
What is Repligen’s market cap?
Repligen’s market cap is $8.99B.
When is Repligen’s upcoming earnings report date?
Repligen’s upcoming earnings report date is Feb 19, 2025 which is in 30 days.
How were Repligen’s earnings last quarter?
Repligen released its earnings results on Nov 12, 2024. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.335 by $0.095.
Is Repligen overvalued?
According to Wall Street analysts Repligen’s price is currently Undervalued.
Does Repligen pay dividends?
Repligen does not currently pay dividends.
What is Repligen’s EPS estimate?
Repligen’s EPS estimate is 0.41.
How many shares outstanding does Repligen have?
Repligen has 56,026,726 shares outstanding.
What happened to Repligen’s price movement after its last earnings report?
Repligen reported an EPS of $0.43 in its last earnings report, beating expectations of $0.335. Following the earnings report the stock price went up 6.508%.
Which hedge fund is a major shareholder of Repligen?
Currently, no hedge funds are holding shares in RGEN
---
Repligen Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$198.17 (23.46% Upside)
$198.17 (23.46% Upside)
Blogger Sentiment
Neutral
RGEN Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 38.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.7%
Last 30 Days ▲ 7.0%
Last 30 Days ▲ 7.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.01%
12-Months-Change
Fundamentals
Return on Equity
-0.41%
Trailing 12-Months
Asset Growth
12.21%
Trailing 12-Months
Company Description
Repligen
Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification, and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.
---
RGEN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment with strong revenue and order growth, particularly in new modalities and CDMO performance. Regional growth was robust except for China, where challenges persist. While emerging biotech and clinical trial starts are a concern, the company's improved guidance and strategic initiatives indicate confidence moving forward.Read More>---
RGEN Revenue Breakdown
44.00% North America
37.00% Europe
19.00% APAC/Other
---
RGEN Stock 12 Month Forecast
Average Price Target
$198.17
▲(23.46% Upside)
Technical Analysis
Best Analysts Covering RGEN
1 Year
1 Year Success Rate
13/20 ratings generated profit
1 Year Average Return
+25.00%
reiterated a buy rating 2 months ago
Copying Daniel Arias's trades and holding each position for 1 Year would result in 65.00% of your transactions generating a profit, with an average return of +25.00% per trade.
---